Corneal Toxicity in Patients Receiving Antibody–Drug Conjugates for the Treatment of Cancer

Download All
Learn from experts about the monitoring and management recommendations for corneal events associated with antibody–drug conjugates used to treat patients with cancer. Review expert insights in a clinical commentary along with downloadable slides, and on-demand webcast adapted from a live CCO webinar.
Asim V. Farooq, MD
Joann Kang, MD
Paul G. Richardson, MD

On-Demand Webcast

In this on-demand webcast, Asim V. Farooq, MD; Joann Kang, MD; and Paul G. Richardson, MD, review the pathophysiology of ocular toxicities caused by antibody–drug conjugates used to treat cancer and provide guidelines on monitoring and managing these toxicities.

Asim V. Farooq, MD Joann Kang, MD Paul G. Richardson, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: January 5, 2022 Expired: January 4, 2023
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
GlaxoSmithKline

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings